Hot Topics Archives | Report Store | Pharma intelligence

show blocks helper

Sort by Default Order
- Default Order
- Name
- Price
- Date
- Popularity

Click to order products descending

Display 15 Products per page

JP Morgan Healthcare Conference Review
$3,000.00
The 2018 JP Morgan Healthcare Conference held in San Francisco over 8–11 January 2018 was light on big news and deals, but PharmaVitae picked up on key themes for some of the presenting companies in our coverage universe, which are all experiencing and/or pursuing a change of scene and pace in dealmaking activity.
January 18, 2018
More information
JP Morgan Healthcare Conference Preview
$3,000.00
PharmaVitae previews companies presenting at the JP Morgan Healthcare Conference to be held in San Francisco over 8–11 January 2018.
January 10, 2018
More information
PD-1/PD-L1 Inhibitors: The First Major Wave of Immuno-Oncology
$7,500.00
Since Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) first gained Japanese regulatory approval for the treatment of metastatic melanoma in July 2014, programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors have grown to become the leading class of immunotherapies in oncology worldwide.
August 16, 2017
More information
Pharma-Payer Partnerships in Emerging Markets
$2,995.00
Payer partnerships are becoming widespread as emerging markets become wealthier, but access challenges remain. Partnerships with proven success include “strategic philanthropy,” patient access programs, tiered pricing, and service support models.
July 26, 2017
More information
Regenerative Medicine Landscape
$2,995.00
The competitive landscape for regenerative medicine continues to evolve. As private sector investment in active players continues, efforts by governments in the US and EU are helping to advance the field, including the recent passage of the 21st Century Cures Act in the US, providing a special status pathway for regenerative medicine advanced therapies.
July 21, 2017
More information
Immuno-Oncology Deal Trends, 2012–16
$2,995.00
Immuno-oncology is an emerging field in medicine that has the potential to radically change how cancer is treated.
April 19, 2017
More information
Big Pharma Licensing Trends, 2012–16
$2,995.00
Between 2012 and 2016, Big Pharma – a peer set of approximately 16 firms across the world with large R&D and sales organizations, and annual revenues in excess of $10bn – signed over 1,200 drug-focused deals, growing at a compound annual growth rate of 12%.
March 8, 2017
More information
Mid Pharma Licensing and M&A Trends, 2011–16
$2,995.00
This analysis covers trends in alliance and mergers and acquisitions (M&A) agreements by Datamonitor Healthcare’s Mid Pharma peer set from 1 January 2011 through to 30 September 2016. Only deals involving drug discovery, development, or commercialization were considered for this analysis. All data were derived from Informa’s Strategic Transactions and Medtrack databases.
February 16, 2017
More information
Social Media in Pharma
$2,995.00
While social media is still relatively new, it has been heralded as one of the most significant changes in the way that people communicate with one another. Despite this, the pharmaceutical industry has been slow to become involved with social media, fearing compliance and regulatory breaches and preferring to stay with the more traditional routes of communication, such as representative visits and emails. However, the growing popularity of social media, combined with a number of positive examples from both within and outside the pharmaceutical industry, has led to an increasing number of pharmaceutical companies looking to grow their social media presence and build on the unique opportunities these platforms offer.
January 27, 2017
More information
Oncology Market Access in Latin America
$2,995.00
Latin America’s multi-billion dollar pharmaceutical markets have attracted controversy related to intellectual property in recent times, but oncology remains a key growth area in the region.
December 22, 2016
More information
Orphan Drug Market Outlook to 2017
$3,000.00
Tumbling over the patent cliff, many Big Pharma companies are being forced to find new strategies for sustaining sales growth, wherever possible minimizing the risk of generic competition.
September 28, 2016
More information
Q2 2016 Earnings Previews
$3,000.00
Datamonitor Healthcare previews Q2 2016 earnings for companies in the PharmaVitae portfolio. Companies will be continuously added the day before presentations.

More information

Hot Topics

Hot Topics

JP Morgan Healthcare Conference Review

JP Morgan Healthcare Conference Preview

PD-1/PD-L1 Inhibitors: The First Major Wave of Immuno-Oncology

Pharma-Payer Partnerships in Emerging Markets

Regenerative Medicine Landscape

Immuno-Oncology Deal Trends, 2012–16

Big Pharma Licensing Trends, 2012–16

Mid Pharma Licensing and M&A Trends, 2011–16

Social Media in Pharma

Oncology Market Access in Latin America

Orphan Drug Market Outlook to 2017

Q2 2016 Earnings Previews